Tandem Diabetes Care, Inc. (TNDM) Q2 2024 Earnings Call Transcript
Tandem Diabetes Care, Inc. (NASDAQ:TNDM ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Susan Morrison - Executive Vice President and Chief Administrative Officer. John Sheridan - President and Chief Executive Officer Mark Novara - Executive Vice President and Chief Commercial Officer Leigh Vosseller - Executive Vice President and Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets.
Tandem Diabetes Care (TNDM) Reports Q2 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Tandem Diabetes Care (TNDM) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Tops Revenue Estimates
Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.30 per share a year ago.
Tandem Diabetes (TNDM) Posts Positive Data for Tandem Mobi
Tandem Diabetes Care, Inc. TNDM announced the latest real-world insights from a user satisfaction survey on their Tandem Mobi system during the 84th Scientific Sessions of the American Diabetes Association (“ADA”) in Orlando, FL. Data from the survey demonstrated that Tandem Mobi helps improve the quality of life for patients with type 1 diabetes.
Here's Why You Should Hold on to Tandem Diabetes (TNDM) Now
Innovations and a robust diabetes market outlook raise investors' optimism for Tandem Diabetes (TNDM).
Tandem Diabetes (TNDM) Connects Mobi Pump With Dexcom G7 Sensor
Tandem Diabetes' (TNDM) Mobi insulin pump is now compatible with Dexcom G7 CGM.
Tandem Diabetes Care: Recent Rally Fully Deserved, Likely More Upside Here
Tandem Diabetes Care is a company that specializes in diabetes management products, most notably insulin pumps for T1D patients. TNDM stock has been performing well, with a 100% increase in value over the past year. Shares traded at >$150 per share in 2021, before a torrid bear run dragged it to
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Sold by Swiss National Bank
Swiss National Bank reduced its position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Free Report) by 9.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 128,200 shares of the medical device company’s stock after selling 13,800 shares during the quarter. Swiss National Bank owned about 0.20% of Tandem Diabetes Care worth $3,792,000 at the end of the most recent reporting period. A number of other hedge funds have also modified their holdings of the business. RiverPark Advisors LLC acquired a new stake in Tandem Diabetes Care during the 4th quarter worth $27,000. Signaturefd LLC raised its stake in Tandem Diabetes Care by 871.8% during the 4th quarter. Signaturefd LLC now owns 1,691 shares of the medical device company’s stock valued at $50,000 after acquiring an additional 1,517 shares during the last quarter. GAMMA Investing LLC acquired a new stake in Tandem Diabetes Care during the 4th quarter worth approximately $73,000. PNC Financial Services Group Inc. grew its stake in shares of Tandem Diabetes Care by 51.7% in the 3rd quarter. PNC Financial Services Group Inc. now owns 3,226 shares of the medical device company’s stock valued at $67,000 after purchasing an additional 1,099 shares during the last quarter. Finally, Creative Financial Designs Inc. ADV acquired a new position in shares of Tandem Diabetes Care in the fourth quarter valued at approximately $104,000. Analyst Upgrades and Downgrades A number of research firms recently weighed in on TNDM. Piper Sandler restated an “overweight” rating and issued a $50.00 price target (up from $35.00) on shares of Tandem Diabetes Care in a research note on Friday, May 3rd. Leerink Partnrs upgraded shares of Tandem Diabetes Care from a “market perform” rating to an “outperform” rating in a research report on Thursday, April 25th. SVB Leerink upgraded shares of Tandem Diabetes Care from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $34.00 to $45.00 in a research report on Thursday, April 25th. Citigroup upped their price target on Tandem Diabetes Care from $31.00 to $38.00 and gave the stock a “neutral” rating in a report on Wednesday, April 3rd. Finally, Stifel Nicolaus lifted their price objective on Tandem Diabetes Care from $37.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, April 23rd. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, Tandem Diabetes Care presently has a consensus rating of “Moderate Buy” and an average target price of $43.80. Check Out Our Latest Analysis on Tandem Diabetes Care Tandem Diabetes Care Stock Performance NASDAQ TNDM opened at $47.30 on Monday. Tandem Diabetes Care, Inc. has a twelve month low of $13.82 and a twelve month high of $47.88. The business’s 50-day moving average price is $35.59 and its 200 day moving average price is $28.04. The company has a current ratio of 3.81, a quick ratio of 3.01 and a debt-to-equity ratio of 1.43. The company has a market capitalization of $3.06 billion, a PE ratio of -21.80 and a beta of 1.10. Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) last issued its quarterly earnings results on Wednesday, February 21st. The medical device company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The company had revenue of $196.80 million for the quarter, compared to analyst estimates of $204.86 million. Tandem Diabetes Care had a negative return on equity of 34.38% and a negative net margin of 18.37%. On average, research analysts predict that Tandem Diabetes Care, Inc. will post -1.7 earnings per share for the current year. Tandem Diabetes Care Profile (Free Report) Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.
Tandem Diabetes (TNDM) Hits 52-Week High: What's Driving It?
Tandem Diabetes (TNDM) outperforms the industry, owing to its impressive series of product launches and an impressive quarterly performance.
